To carry out their activities, Research Teams of the Frédéric Joliot Institute for Life Sciences have developed high-profile technological platforms in many areas : biomedical imaging, structural biology, metabolomics, High-Throughput screening, level 3 microbiological safety laboratory...
All the news of the Institute of life sciences Frédéric Joliot
Scientific result | Positron Emission Tomography | Cancer
Researchers from BioMaps (SHFJ) and the SIMoS (DMTS) have developed optimized radioligands for immunoPET imaging. The objective is to better predict the effectiveness of anti-PD1/anti-PDL1 immunotherapy used to fight certain cancers.
Often better tolerated than chemotherapy, immunotherapy is increasingly used to fight cancers. The main pitfall of this therapeutic strategy is that a significant proportion of patients do not respond. For example, in non-small cell lung cancer, only 10-20% of patients respond to anti-PD-1/anti-PD-L1 monoclonal antibody immunotherapy (see box). Although high PD-L1 expression is associated with a better therapeutic response, there is a lack of reliable markers to predict whether or not a patient will respond to an injection of anti-PD-1/anti-PD-L1 antibodies.
ImmunoPET imaging with radiolabeled ligands directed against PD-L1 is a technology that offers the possibility to visualize and quantify in real time and non-invasively the expression of PD-L1 in all tumor lesions, including those difficult to reach by biopsy. In addition, this allows for more accurate prediction of immunotherapy efficacy and longitudinal follow-up to tailor the therapeutic strategy to each patient.
Ideally, a good anti-PD-L1 radioligand should both penetrate and diffuse rapidly into the tumor tissue, while being rapidly cleared from the bloodstream, in order to obtain high contrast PET images with short post-injection times. The examination can then be performed only a few hours after administration of the anti-PD-L1 radioligand.
In addition to radiolabeled antibodies (89Zr-atezolizumab, 89Zr-avelumab or 89Zr-IgG C4), various formats of anti-PD-L1 radioligands with faster pharmacokinetics (PK) have been developed in order to optimize anti-PD-L1 immunoPET imaging, ranging from antibody fragments to small synthetic proteins. This is notably the case in a new study conducted by a team from BioMaps (SHFJ, for radiolabeling and in vivo PK study), in collaboration with the Laboratory of Cellular Immunogenicity and Biotechnologies (LICB, SIMoS/DMTS, for ligand production). To do so, the researchers first produced three radioligands - IgG C4; IgG C4 with a mutation on the Fc chain (H310A/H435Q) and Fab C4, all radiolabeled with 89Zr , and then compared their characteristics by PET/CT imaging in murine mice bearing a subcutaneous non-small cell lung cancer (NSCLC) xenograft. The conclusive results highlighted the potential of manufacturing smaller radioligands with shorter pharmacokinetics for PD-L1 immunoPET imaging in a preclinical model, encouraging further clinical application of such radioligands.
Alizée Bouleau, Hervé Nozach, Steven Dubois, Dimitri Kereselidze, Céline Chevaleyre, Cheng-I Wang, Michael J. Evans, Vincent Lebon, Bernard Maillère, Charles Truillet. Optimizing immunoPET imaging of tumor PD-L1 expression: pharmacokinetics, biodistribution and dosimetric comparisons of 89Zr-labeled anti-PD-L1 antibody formats. | Journal of Nuclear Medicine, December 2021, jnumed.121.262967
CEA is a French government-funded technological research organisation in four main areas: low-carbon energies, defense and security, information technologies and health technologies. A prominent player in the European Research Area, it is involved in setting up collaborative projects with many partners around the world.